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Abstract
:  Hypertension is a serious medical problem affecting a large population worldwide. Liddle
syndrome is a hereditary form of early onset hypertension caused by mutations in the epithelial
Na+ channel (ENaC). The mutated region, called the PY (Pro-Pro-x-Tyr) motif, serves as a binding
site for Nedd4-2, an E3 ubiquitin ligase from the HECT family. Nedd4-2 binds the ENaC PY motif
via its WW domains, normally leading to ENaC ubiquitylation and endocytosis, reducing the
number of active channels at the plasma membrane. In Liddle syndrome, this endocytosis is
impaired due to the inability of the mutated PY motif in ENaC to properly bind Nedd4-2. This leads
to accumulation of active channels at the cell surface and increased Na+ (and fluid) absorption in
the distal nephron, resulting in elevated blood volume and blood pressure. Small molecules/
compounds that destabilize cell surface ENaC, or enhance Nedd4-2 activity in the kidney, could
potentially serve to alleviate hypertension.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway involvement in disease
Introduction
Elevated arterial blood pressure, or hypertension, poses a
serious public health problem, affecting approximately
25% of the adult population in the industrial world [1],
and becoming, along with obesity, a serious health prob-
lem in the developing world as well. In recent years, the
causes of several genetic disorders leading to hypertension
or hypotension have been identified, and deleterious
mutations have been mapped to components of the
aldosterone pathway, as well as to key ion channels and
transporters expressed along the nephron. Prominent
examples include Bartter syndrome type I, II or III, Gitel-
man syndrome, pseudohypoaldosteronism I (PHAI) and
Liddle syndrome [2]; the latter two are associated with
mutations in the epithelial Na+ channel (ENaC) and are
discussed in this review, with a particular focus on Liddle
syndrome, a hereditary form of hypertension.
The epithelial Na+ channel
The amiloride-sensitive ENaC is an ion channel expressed
in Na+-transporting epithelia such as those present in the
distal nephron, respiratory epithelium, distal colon and
taste buds [3]. In the kidney, it is primarily expressed in
the distal connecting tubules (CNTs) and cortical collect-
ing tubules (CCTs) of the nephron [4,5], where it provides
the rate limiting step for Na+ (and fluid) reabsorption into
the blood stream [3,6,7]. This regulation of Na+ and fluid
absorption is tightly controlled by the hormones aldoster-
one (i.e. the renin-angiotensin-aldosterone pathway) and
vasopressin (antidiuretic hormone, ADH), which stimu-
late channel activity [6,8]. The single channel characteris-
tics of ENaC reveal high selectivity for Na+ over K+, low
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single channel conductance (~5 pS), high sensitivity to
amiloride (~100 nM) and slow gating [6]. ENaC activity is
primarily regulated by control of its opening (Po) and
numbers at the plasma membrane [8].
ENaC is comprised of three subunits, α, β and γ [9], each
consisting of two transmembrane domains flanked by a
large extracellular loop and two intracellular N- and C-ter-
mini, and is preferentially assembled at a stoichiometry of
α2βγ [10,11] (although other configurations have been
proposed [12,13]). Maximal channel activity is obtained
when all three subunits are expressed together, but expres-
sion of α alone, or a combination of αβ, or αγ, results in
low or moderate channel activity, respectively [9].
Genetic disease-causing mutations in ENaC, as well as
mouse models, have shed important light on ENaC func-
tion and the pathology of ENaC-related diseases. For
example, loss of function mutations in either α, β, or γ
ENaC cause PHAI [14,15], a salt-wasting disease leading
to hypotension, which is also mimicked in knockout
mouse models lacking β or γ ENaC [16,17], or models
expressing reduced levels of α ENaC [18], all of which
exhibit reduced levels of channel expression and activity
[9,19]. In contrast to the ENaC loss of function mutations
causing PHAI, gain of function mutations in this channel
cause Liddle syndrome.
Liddle syndrome
Liddle syndrome (pseudoaldosteronism, OMIM 177200)
is an autosomal dominant disease leading to early onset
of hypertension. It is associated with hypokalemic alkalo-
sis, reduced plasma rennin activity and low plasma aldos-
terone levels [20]. Over the past 12 years, work from
Lifton's group (Yale University) and others has identified
several deletions/mutations that cause Liddle syndrome,
all of which map to β or γ ENaC and lead to elevated chan-
nel numbers and activity at the plasma membrane, as
assessed by heterologously expressing these mutant
ENaCs in Xenopus oocytes or cultured mammalian cells
[2,21,22]. These genetic defects either delete the C-termi-
nus of β or γ ENaC [23,24], or mutate a proline or a tyro-
sine within a short sequence, called the PY (Pro-Pro-x-Tyr)
motif [25-28]. The PY motif, or extended PY motif (PPx-
YxxL [21,29]), is highly conserved in the C-termini of all
ENaC subunits [26], and serves as a binding site for the
Nedd4 family of ubiquitin ligases [30], as assessed by in
vitro binding, yeast two-hybrid and co-immunoprecipita-
tion assays, as well as by structural analysis (e.g. [29,30]).
Regulation of ENaC by the ubiquitin system and its 
impairment in Liddle syndrome
Ubiquitylation, carried out by the sequential activity of
E1, E2 and E3 (ubiquitin ligase) enzymes, usually regu-
lates stability of target proteins that are tagged with ubiq-
uitin by the E3 ligases [31]. Most of these proteins are
degraded by the proteasome [32]. Recent studies have
demonstrated, however, that ubiquitylation of transmem-
brane proteins can tag them for endocytosis and/or vesic-
ular sorting, often resulting in their degradation in the
lysosome [33,34]. This is usually achieved by the presence
of ubiquitin binding motifs or domains (e.g. UIM, UBA,
C U E ,  G A T ,  U E V ,  V H S )  w i t h i n  p r o t e i n s  s u c h  a s  e p s i n /
Eps15, Hrs and GGA, which function to recognize the
ubiquitylated transmembrane proteins and facilitate their
endocytosis or sorting [35].
Nedd4 family members are E3 ubiquitin ligases that com-
prise a C2 domain responsible for membrane targeting
[36,37], three to four WW domains that bind the PY
motifs of ENaC [29,30,38-42], and a ubiquitin ligase
HECT (homologous to E6AP carboxyl-terminus) domain
[43,44] (Figures 1 and 2). Of the two closely related
Nedd4 members, Nedd4-1 and Nedd4-2, the latter binds
ENaC more strongly due to the presence of an additional,
high affinity WW domain (WW3, out of four WW
domains) [41,42]. Accordingly, Nedd4-2 was shown to
effectively suppress ENaC activity by enhancing removal
of the channel from the plasma membrane [45-47], and
ubiquitylation of ENaC was demonstrated to destabilize
cell surface ENaC [48] (Figure 2). Indeed, our recent work
has demonstrated that Nedd4-2 can ubiquitylate ENaC
present at the apical membrane of cultured kidney epithe-
lial cells [49]. The few Nedd4-1 proteins that also contain
this high affinity WW3 domain (e.g. human and Dro-
sophila Nedd4-1) are also able to suppress ENaC activity
when heterologously expressed in Xenopus oocytes or cul-
tured cells, although in some cases this is prevented in the
presence of the C2 domain (for example, in the case of
human Nedd4-1 [41,47,50]), possibly (albeit specula-
tively) due to inhibitory interactions between the C2 and
HECT domains.
Experiments performed in Xenopus oocytes or mammalian
cultured cells that ectopically express ENaC reveal that
unlike the ability of Nedd4-2 to induce removal of wild-
type ENaC from the plasma membrane by ubiquitylation
(likely linked to subsequent clathrin-mediated endocyto-
sis [51]), Liddle syndrome mutations in the PY motif of β
or  γ ENaC severely attenuate this removal, leading to
increased retention of mutant ENaC at the cell surface and
to elevated channel activity [45,46,49] (Figure 2). Accord-
ingly, conditional knockout mice bearing a deletion of the
PY motif in βENaC (a mouse model for Liddle syndrome)
develop hypertension that is induced by high salt diet
[52]. Moreover, channel feedback inhibition by elevated
intracellular Na+ concentrations exhibited by wild-type
ENaC (demonstrated ex vivo in the CCTs of rats [53]) is
defective in ENaC bearing the Liddle syndrome mutations
in the PY motif (as shown by ectopic expression of PYBMC Biochemistry 2008, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2091/9/S1/S5
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motif-mutated ENaC in Xenopus  oocytes [54]), further
exacerbating Na+  loading. Together, this results in
increased Na+ and fluid reabsorption in the distal neph-
ron, and increased blood volume and blood pressure,
which are hallmarks of Liddle syndrome.
As indicated in the section The epithelial Na+channel, ENaC
is tightly (positively) regulated in the kidney by the min-
eralocorticoid hormone aldosterone. One of the recently
discovered aldosterone targets is Sgk1, a Ser/Thr kinase
from the Akt (PKB) family that was found to elevate ENaC
levels/activity in response to aldosterone in rat or mouse
kidney and in A6 cells (a Xenopus cell line endogenously
expressing ENaC and responsive to aldosterone) [55,56].
This effect can be mediated either without (see below) or
via regulation of Nedd4-2 (Figure 1). Nedd4-2 (but not
Nedd4-1) possesses Sgk1 phosphorylation sites and,
when phosphorylated by Sgk1 (in cultured cells), is pre-
vented from downregulating ENaC, leading to increased
ENaC retention at the cell surface and thus increased
ENaC activity [57,58]. This effect is believed to be medi-
ated by association of the adaptor protein 14-3-3, known
to bind phosphoSer/Thr [59], with Ser-phosphorylated
Nedd4-2, thus preventing Nedd4-2 from binding ENaC
[60,61] (by as yet unknown mechanism(s)). In support,
the expression of 14-3-3β and Nedd4-2, as well as Nedd4-
2 phosphorylation, were recently shown to be induced in
CCT cells by dietary salt and by aldosterone [62-64]. How-
ever, aldosterone and Sgk1 can stimulate ENaC independ-
ently of Nedd4-2 and their role in Liddle syndrome is
controversial: aldosterone and Sgk1 were found to
increase cell surface abundance of ENaC channels bearing
Liddle syndrome deletions/mutations (which cannot
bind Nedd4-2) [65-68] and, importantly, CCTs harvested
from mutant mice bearing a Liddle syndrome deletion
[52] revealed a normal response to aldosterone [69].
In addition to aldosterone, the hormone vasopressin also
increases ENaC activity (as well as water absorption) in
the distal nephron by binding to V2 receptors and stimu-
Regulation of ENaC by Nedd4-2 in homeostasis Figure 1
Regulation of ENaC by Nedd4-2 in homeostasis. The ubiquitin ligase Nedd4-2 binds (via its WW domains) to the PY 
motifs of ENaC, in turn ubiquitylating and targeting ENaC for endocytosis and lysosomal degradation. This process can be 
inhibited by Sgk1- or Akt-mediated phosphorylation of Nedd4-2, which leads to binding of 14-3-3 proteins to phosphorylated 
Nedd4-2, thus preventing Nedd4-2 from associating with ENaC and thus increasing ENaC levels at the plasma membrane. Sgk1 
can also upregulate ENaC independently of Nedd4-2.BMC Biochemistry 2008, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2091/9/S1/S5
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lating activation of adenylate cyclase and the release of
cAMP [6]. cAMP increases the density of ENaC channels
(endogenously or ectopically expressed in epithelial cells)
at the plasma membrane [70,71], an effect suggested to be
impaired in channels bearing the Liddle syndrome PY
motif mutations due to defective trafficking to the cell sur-
face [72], or mobilization from a sub-apical pool [49].
Recent studies also suggested that Nedd4-2 phosphoryla-
tion by PKA (which is activated by cAMP) provides inhib-
itory function much like Sgk1, thus inhibiting the ability
of Nedd4-2 to suppress ENaC, leading to increased cell
surface abundance of this channel [73].
Among the other factors that regulate ENaC (aside from
hormones, ions and Nedd4-2), are proteases such as CAP
proteins and TMPRSS3, which activate ENaC by proteo-
lytic cleavage of its ectodomains [3,74-77]. A recent paper
suggests that Liddle syndrome mutations increase the
number of cleaved (active) ENaCs at the cell surface (thus
further increasing Na+ absorption), and that Nedd4-2 and
ENaC ubiquitylation regulate the number of cleaved
channels at the plasma membrane [78].
Disease models, knockouts and assays
To date, only one mouse model for Liddle syndrome has
been generated. These mice, created by the Rossier/
Hummler groups (Institut de Pharmacologie et de Toxi-
cologie, Switzerland) in 1999, bear a deletion of the PY
motif in βENaC (a stop codon is inserted at a residue cor-
responding to residue Arg566 in human βENaC, as found
in the original pedigree described by R. Lifton [23]). The
mice have no phenotype under a normal salt diet, but
develop hypertension when fed a high salt diet [52]. To
date, no other relevant knockout mice of Liddle syndrome
have been developed.
Disease targets and ligands
Liddle syndrome patients are treated with the ENaC
antagonist amiloride-triamterene and a low salt diet to
stabilize their high blood pressure. While Liddle syn-
drome is a rare disorder, as are several genetic forms of
hypertension [2], other forms of hypertension are very
common in the population and have no known genetic
components. Inhibiting ENaC activity, the rate limiting
step in the regulation of Na+ and fluid reabsorption in the
nephron, could provide an attractive target to treat hyper-
tension. With the advent of high throughput technology it
is possible to test for inhibition of ENaC activity by
screening with small molecules/compound libraries, with
the hope of identifying inhibitory compounds that may
be superior to amiloride and its analogs. In that regard, we
have recently developed a high throughput assay that
allows quantification of the amounts of cell surface ENaC
(Chen and Rotin, unpublished). Given the key role played
by the ubiquitin system/Nedd4-2 in regulating ENaC cell
surface stability and ENaC function, identifying com-
pounds that destabilize/decrease ENaC levels at the
plasma membrane could have potential therapeutic ben-
efits for the treatment of hypertension. Stimulating
Nedd4-2 activity, which leads to ENaC endocytosis/degra-
dation, could also be a possibility. However, since Nedd4-
2 likely has other targets in other tissues/cells, this
approach needs to be scrutinized to ensure it is targeted
specifically to ENaC in the kidney. It is likely that use of
putative compounds that aim to enhance ENaC internali-
zation or Nedd4-2 activity would be more effective
towards other forms of hypertension and not Liddle syn-
drome, since the latter carries mutations that already
inhibit ENaC internalization and are insensitive to
Nedd4-2.
New frontiers in drug discovery
Despite significant recent advances, several key questions
remain to be answered regarding the regulation of ENaC
by Nedd4-2 and the ubiquitin system. These include:
(i) How is sensing of elevation of intracellular concentra-
tions of Na+ (that normally shuts down ENaC) related to
the Liddle syndrome mutations? If this is regulated via
Nedd4-2, how is Nedd4-2 (directly or indirectly) able to
sense Na+?
(ii) How does phosphorylation of Nedd4-2 by Sgk1 (on
sites not within the WW domains), which leads to binding
Regulation of ENaC by Nedd4-2 and its impairment in Liddle  syndrome Figure 2
Regulation of ENaC by Nedd4-2 and its impairment 
in Liddle syndrome. In Liddle syndrome, deletion/mutation 
of the PY motif in βENaC (or γENaC, not shown) impairs the 
ability of Nedd4-2 to bind (and thus ubiquitylate) ENaC, lead-
ing to accumulation of ENaC channels at the plasma mem-
brane and increased channel activity. (Modified with 
permission from Staub and Rotin).BMC Biochemistry 2008, 9(Suppl 1):S5 http://www.biomedcentral.com/1471-2091/9/S1/S5
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of 14-3-3 to Nedd4-2, inhibit the association of Nedd4-2
with ENaC, which is mediated via the WW domains?
(iii) What is the exact stoichiometry of Nedd4-2-ENaC
interactions, and how is it that loss of only one PY motif
is sufficient to cause Liddle syndrome?
(iv) How is the activity of Nedd4-2 itself regulated in the
cell?
(v) What is the physiological function of Nedd4 proteins
in vivo in mammals, especially in the kidney? The latter
should be answered with the generation of knockout
murine models for these proteins (not yet published).
Future work will undoubtedly address these and other
important questions that investigate the relationship
between ENaC and the ubiquitin system.
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